SCHEMBL20543711

SCHEMBL20543711

O=c1c(Cc2ccco2)nc2c(Cc3cccc(F)c3)[nH]c(-c3ccccc3)cn1-2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.43
▸ TSHR P16473 3/20 0.43
▸ MAPK1 P28482 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ PLA2G7 Q13093 1/20 0.37
▸ PRNP P04156 2/20 0.35
▸ HPN P05981 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ ADORA2A P29274 3/20 0.33
▸ ADORA2B P29275 3/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ PKM P14618 2/20 0.33
▸ CHRNA7 P36544 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30110494 1.00 ALDH1A1 (0.43) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL27213496 0.95 ALDH1A1 (0.41) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL20543423 0.91 PDE3B (0.38) ALDH1A1MAPK1SMN1; SMN2USP2CYP1A2
SCHEMBL2670126 0.91 ALDH1A1 (0.39) ALDH1A1TSHRLMNAHTTUSP2
SCHEMBL20543595 0.91 PDE3B (0.38) ALDH1A1MAPK1SMN1; SMN2USP2CYP1A2
SCHEMBL19810212 0.90 ALDH1A1 (0.38) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL19810310 0.89 ADORA2B (0.38) ALDH1A1TSHRLMNAHTTUSP2
SCHEMBL20543673 0.86 THRB (0.39) ALDH1A1SMN1; SMN2ADORA2AADORA2BPDE3B
SCHEMBL30110604 0.86 THRB (0.39) ALDH1A1SMN1; SMN2ADORA2AADORA2BPDE3B
SCHEMBL20543878 0.86 HPN (0.35) ALDH1A1MAPK1SMN1; SMN2HPNUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3964501-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2024-09-04 — — EP claimed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 — — US claimed
EP-3964501-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2022-03-09 — — EP claimed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US claimed
EP-3395803-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2018-10-31 — — EP claimed
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-04-28 — — US disclosed
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-03-17 — — US disclosed
US-20240361321-A1 LUMINESCENT BASED ANTIGEN ASSAY INSTITUT PASTEUR (FR) 2024-10-31 — — US disclosed
EP-3964501-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2024-09-04 — — EP disclosed
EP-4392460-A1 LUMINESCENT BASED ANTIGEN ASSAY Institut Pasteur (FR) 2024-07-03 — — EP disclosed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 — — US disclosed
CN-118139895-A Luminescence-based antigen assay 巴斯德研究所 2024-06-04 — — CN disclosed
WO-2023025816-A1 LUMINESCENT BASED ANTIGEN ASSAY INSTITUT PASTEUR (FR) 2023-03-02 — — WO disclosed
CN-115461454-A Luciferase coupled immunosorbent assay 巴斯德研究所 2022-12-09 — — CN disclosed
EP-3964501-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2022-03-09 — — EP disclosed
EP-3615516-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2021-11-17 — — EP disclosed
EP-3904508-A1 LUCIFERASE LINKED IMMUNOSORBENT ASSAY Institut Pasteur (FR) 2021-11-03 — — EP disclosed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US disclosed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US disclosed
EP-3395803-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2018-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 ALDH1A1 972/4885TSHR 3922/4885MAPK1 3559/4885
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, HLCS, LANCL1 ALDH1A1 659/4885TSHR 3191/4885MAPK1 3262/4885
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, MRPL21, CRY1 ALDH1A1 1484/4885TSHR 1083/4885MAPK1 4354/4885
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 ALDH1A1 972/4885TSHR 3922/4885MAPK1 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback